Navigation Links
Prozac Reduces Disease Activity in MS Patients
Date:4/30/2008

Small study finds antidepressant cut inflammation in relapsing remitting illness

WEDNESDAY, April 30 (HealthDay News) -- Prozac may help reduce disease activity in people with the relapsing remitting form of multiple sclerosis (MS), a new study suggests.

Forty patients with the disease were randomly selected to receive either 20 milligrams a day of fluoxetine (Prozac) or a placebo for 24 weeks. MRI brain scans were conducted every four weeks to monitor the patients for new areas of neurological inflammation, a hallmark of disease activity.

Of the 38 patients (19 in each group) who completed the study, those who took the placebo had more new areas of inflammation (average of more than five areas) than those who took the drug (average of just under two).

One in four scans from patients treated with fluoxetine showed new areas of inflammation, compared with four out of 10 scans from patients taking the placebo. During the last 16 weeks of treatment, 63 percent of patients in the fluoxetine group had no new areas of inflammation, compared with 26 percent of those in the placebo group.

The findings were published online in the Journal of Neurology Neurosurgery and Psychiatry.

This was a small study, and larger studies are needed before any firm conclusions about the use of fluoxetine in patients with relapsing remitting MS can be made, the study authors noted.

However, the findings are "sufficiently encouraging to justify further studies with fluoxetine in patients with MS," they said, and added that higher doses and treatment combinations with other drugs that alter the immune response should be considered in future studies.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.



-- Robert Preidt



SOURCE: BMJ Specialist Journals, news release, May 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Prozac Makes Old Brain Cells Young
2. Staff Training Reduces Postpartum Bleeding, Episiotomies
3. Gene Therapy in Rats Reduces Cocaine Use
4. Study shows pine bark naturally reduces osteoarthritis
5. Study Shows Pine Bark Naturally Reduces Osteoarthritis
6. Gene therapy reduces cocaine use in rats
7. Pill Reduces Relapses in MS Patients
8. Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent
9. Essential nutrient found in eggs reduces risk of breast cancer by 24 percent
10. Psychological intervention reduces postembolization pain
11. Aspirin Reduces Asthma Risk Among Older Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... clearly shows that over the last decade, student well-being has seriously declined. "When ... boxes of formal education, join the Islamic State to turn the historic multi-ethnic ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation ... former Chairman of the Board of Directors for CONTACT USA, and former member of ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... Gallardo, DDS, PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium ... , The Oral Reconstruction Foundation will present its annual Global Symposium at the ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... brands, work wear distributors and International relief organizations across the globe to provide ... also offers lifestyle and work wear collections via insectshield.com . In the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... YORK , April 19, 2017 Cardiology devices ... the projected period The Cardiology Devices segment is ... than US$ 15 Mn in 2018 over 2017. By the ... a market valuation close to US$ 700 Mn, expanding at ... Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: